BACKGROUND: To circumvent the challenges associated with delivering large compounds directly to the brain for the treatment of Parkinson's disease (PD), non-invasive procedures utilizing smaller molecules with protective and/or restorative actions on dopaminergic neurons are needed. NEW METHOD: We developed a methodology for evaluating the effects of a synthetic neuroactive peptide, DNSP-11, on the nigrostriatal system using repeated intranasal delivery in both normal and a unilateral 6-hydroxydopamine (6-OHDA) lesion rat model of PD. RESULTS: Normal rats repeatedly administered varying doses of DNSP-11 intranasally for 3 weeks exhibited a significant increase in dopamine (DA) turnover in both the striatum and substantia nigra (SN) at 300μg, suggestive of a stimulative effect of the dopaminergic system. Additionally, a protective effect was observed following repeated intranasal administration in 6-OHDA lesioned rats, as suggested by: a significant decrease in d-amphetamine-induced rotation at 2 weeks; a decrease in DA turnover in the lesioned striatum; and an increased sparing of tyrosine hydroxylase (TH) positive (+) neurons in a specific sub-region of the lesioned substantia nigra pars compacta (SNpc). Finally, tracer studies showed (125)I-DNSP-11 distributed diffusely throughout the brain, including the striatum and SN, as quickly as 30min after a single intranasal dose. COMPARISON WITH EXISTING METHODS: The results of bilateral intranasal administration of DNSP-11 are compared to our unilateral single infusion studies to the brain in rats. CONCLUSIONS: These studies support that DNSP-11 can be delivered intranasally and maintain its neuroactive properties in both normal rats and in a unilateral 6-OHDA rat model of PD.
BACKGROUND: To circumvent the challenges associated with delivering large compounds directly to the brain for the treatment of Parkinson's disease (PD), non-invasive procedures utilizing smaller molecules with protective and/or restorative actions on dopaminergic neurons are needed. NEW METHOD: We developed a methodology for evaluating the effects of a synthetic neuroactive peptide, DNSP-11, on the nigrostriatal system using repeated intranasal delivery in both normal and a unilateral 6-hydroxydopamine (6-OHDA) lesion rat model of PD. RESULTS: Normal rats repeatedly administered varying doses of DNSP-11 intranasally for 3 weeks exhibited a significant increase in dopamine (DA) turnover in both the striatum and substantia nigra (SN) at 300μg, suggestive of a stimulative effect of the dopaminergic system. Additionally, a protective effect was observed following repeated intranasal administration in 6-OHDA lesioned rats, as suggested by: a significant decrease in d-amphetamine-induced rotation at 2 weeks; a decrease in DA turnover in the lesioned striatum; and an increased sparing of tyrosine hydroxylase (TH) positive (+) neurons in a specific sub-region of the lesioned substantia nigra pars compacta (SNpc). Finally, tracer studies showed (125)I-DNSP-11 distributed diffusely throughout the brain, including the striatum and SN, as quickly as 30min after a single intranasal dose. COMPARISON WITH EXISTING METHODS: The results of bilateral intranasal administration of DNSP-11 are compared to our unilateral single infusion studies to the brain in rats. CONCLUSIONS: These studies support that DNSP-11 can be delivered intranasally and maintain its neuroactive properties in both normal rats and in a unilateral 6-OHDArat model of PD.
Authors: Michael F Salvatore; Yi Ai; Brent Fischer; Amanda M Zhang; Richard C Grondin; Zhiming Zhang; Greg A Gerhardt; Don M Gash Journal: Exp Neurol Date: 2006-09-07 Impact factor: 5.330
Authors: John T Slevin; Don M Gash; Charles D Smith; Greg A Gerhardt; Richard Kryscio; Himachandra Chebrolu; Ashley Walton; Renee Wagner; A Byron Young Journal: Neurosurg Focus Date: 2006-05-15 Impact factor: 4.047
Authors: Piotr Hadaczek; Yoji Yamashita; Hanna Mirek; Laszlo Tamas; Martha C Bohn; Charles Noble; John W Park; Krystof Bankiewicz Journal: Mol Ther Date: 2006-05-02 Impact factor: 11.454
Authors: Lusine Danielyan; Richard Schäfer; Andreas von Ameln-Mayerhofer; Marine Buadze; Julia Geisler; Tim Klopfer; Ute Burkhardt; Barbara Proksch; Stephan Verleysdonk; Miriam Ayturan; Gayane H Buniatian; Christoph H Gleiter; William H Frey Journal: Eur J Cell Biol Date: 2009-03-25 Impact factor: 4.492
Authors: M J Stenslik; A Evans; F Pomerleau; R Weeks; P Huettl; E Foreman; J Turchan-Cholewo; A Andersen; W A Cass; Z Zhang; R C Grondin; D M Gash; G A Gerhardt; L H Bradley Journal: J Neurosci Methods Date: 2018-03-31 Impact factor: 2.390